Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells

Endocrinology

Volumn 148, Issue 11, 2007, Pages 5186-5194

  Libertini, Silvana ^a   Iacuzzo, Irma ^a   Ferraro, Angelo ^b   Vitale, Mario ^a   Bifulco, Maurizio ^c   Fusco, Alfredo ^a,b   Portella, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Centro di Ingegneria Genetica e Biotecnologia Avanzate CEINGE   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MEVINOLIN; ONYX 015;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR GROWTH; VIRUS REPLICATION; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELLS, CULTURED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LOVASTATIN; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; THYROID NEOPLASMS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 35548988970     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-0752     Document Type: Article

References (29)

1. Hedinger C, Williams ED, Sobin LH 1989 The WHO histological classification of thyroid tumours: a commentary on the second edition. Cancer 63:908-911
2. Ain KB 2000 Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab 14:615-629
3. Nikiforov YE 2004 Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 15:319-327
4. Sherman SI 2003 Thyroid carcinoma. Lancet 361:501-511
5. Parato KA, Senger D, Forsyth PA, Bell JC 2005 Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 12:965-976
6. Kruyt FA, Curiel DT 2002 Toward a new generation of conditionally replicating adenoviruses: pairing tumor selectivity with maximal oncolysis. Hum Gene Ther 13:485-495
7. Post DE, Khuri FR, Simons JW, Van Meir EG 2003 Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 14:933-946
8. Portella G, Scala S, Vitagliano D, Vecchio G, Fusco A. 2002 ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 87:2525-2531
9. Portella G, Pacelli R, Libertini S, Cella L, Vecchio G, Salvatore M, Fusco A 2003 ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:5027-5032
10. Graaf MR, Richel DJ, Van Noorden CJ, Guchelaar HJ 2004 Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30:609-641
11. Chan KK, Oza AM, Siu LL 2003 The statins as anticancer agents. Clin Cancer Res 9:10-19
12. Wang CY, Zhong WB, Chang TC, Lai SM, Tsai YF 2003 Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:3021-3026
13. Zhong WB, Wang CY, Chang TC, Lee S 2003 Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 144:3852-3859
14. Fiore L, Pollina LE, Fontani G, Casalone R, Berlingieri MT, Giannini R, Pacini F. Miccoli P, Toniolo A, Fusco A, Basolo F 1997 Cytokine production by a new undifferentiated human thyroid carcinoma cell line, FB-1. J Clin Endocrinol Metab 82:4094-4100
15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren J T, Bokesch H, Kenney S, Boyd MR 1990 New colorimetric cytoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112
16. Abou El Hassan MA, Braam SR, Kruyt FA 2006 Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-smallcell lung cancer cells. Cancer Gene Ther 12:1105-1114
17. Hsu LK, Lonberg-Holm K, Alstein B, Crowell RL 1988 A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses. J Virol 62:1647-1652
18. Coyne CB, Bergelson JM 2005 CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev 57:869-882
19. Anders M, Christian C, McMahon M, McCormick F, Korn WM 2003 Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the Coxsackie virus and adenovirus receptor in cancer cells. Cancer Res 63:2088-2095
20. Crompton AM, Kirn DH 2007 From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2:133-2139
21. Marsee DK, Vadysirisack DD, Morrison CD, Prasad ML, Eng C, Duh QY, Rauen KA, Kloos RT, Jhiang SM 2005 Variable expression of Coxsackie-adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy. Thyroid 15:977-987
22. Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, Oft M, Balmain, A, Akhurst RJ, Korn WM 2006 Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and adenovirus receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res 66:1648-1657
23. Zhong WB, Liang YC, Wang CY, Chang TC, Lee WS 2005 Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signalling. Endocr Relat Cancer 3:615-629
24. Li E, Brown SL, Stupack DG, Puente XS, Cheresh DA, Nemerow GR 2001 Integrin α(v)β(1) is an adenovirus coreceptor. J Virol 75:5405-5409
25. Abou El Hassan MA, Braam SR, Kruyt FA 2006 A real-time RT-PCR assay for the quantitative determination of adenoviral gene expression in tumor cells. J Virol Methods 133:53-61
26. Sivaprasad U, Abbas T, Dutta A 2006 Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 5:2310-2316
27. Goldsmith ME, Kitazono M, Fok P, Aikou T, Bates S, Fojo T 2003 The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Clin Cancer Res 9:5394-5401
28. Bieler A, Mantwill K, Dravits T, Bernshausen A, Glockzin G, Kohler-Vargas N, Lage H, Gansbacher B, Holm PS 2006 Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther 17:55-70
29. Dion LD, Goldsmith KT, Tang DC, Engler JA, Yoshida M, Garver Jr RI 1997 Amplification of recombinant adenoviral transgene products occurs by inhibition of histone deacetylase. Virology 231:201-209